Do you want to read an article? Please log in or register.
Association Between Androgen Deprivation Therapy and Risk of Dementia
Genitourinary Cancer
Related content
Genitourinary Cancer
Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer
doi: 10.1016/j.eururo.2018.11.022.
Genitourinary Cancer
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
J Urol.
Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL
doi: 10.1016/j.juro.2016.12.022.
Genitourinary Cancer
Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial
JAMA Oncol.
Royce TJ, Chen MH, Wu J, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV
doi: 10.1001/
Genitourinary Cancer
Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy
Eur Urol.
Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, Carlsson S, Steineck G, Wiklund NP
doi: 10.1016/j.eururo.2017.04.002.
RECOMMENDED
Genitourinary Cancer
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial
JAMA Oncol.
Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard AC, Delva R, Rolland F, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero JM, Ravaud A, Krakowski I, Lagrange JL, Deplanque G, Zylberait D, Bozec L, Houede N, Culine S, Elaidi
doi: 10.1001/jamaoncol.2018.6607.
Genitourinary Cancer
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)
Ann Oncol.
Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, Prayer-Galetti T, Alimonti A
doi: 10.1016/j.annonc.2020.04.479.
Genitourinary Cancer
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
JAMA Oncol.
Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY
doi: 10.1001/jamaoncol.2017.0751.
Genitourinary Cancer
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur J Cancer
Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Wilke D, Souhami L
doi: 10.1016/j.ejca.2020.10.023
RECOMMENDED
Head and Neck Cancer
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma
Eur J Cancer.
van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, Cavalieri S, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML; PALGA Group
doi: 10.1016/j.ejca.2018.12.035.